β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277):: a randomised, double-blind, phase II trial
β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277):: a randomised, double-blind, phase II trial
复制标题
DOI：
10.1016/s0140-6736(01)06801-5
复制
发表时间：
2001-11-24
期刊：
影响因子：
168.9
通讯作者：
Cohen, IR
中科院分区：
文献类型：
--
作者：
Raz, I;Elias, D;Cohen, IR
背景1型糖尿病是由产生胰岛素的胰腺β细胞的自身免疫性破坏引起的。60 kDa热休克蛋白（heat-shock protein，hsp 60）是已知的靶向自身抗原之一。一种来自热休克蛋白60的免疫调节肽p277在新糖尿病NOD小鼠中阻止β细胞破坏并维持胰岛素产生。我们对新近诊断为（
Background Type 1 diabetes results from autoimmune destruction of insulin-producing pancreatic beta cells. The 60 kDa heat-shock protein (hsp60) is one of the known target self antigens. An immunomodulatory peptide from hsp60, p277, arrested beta -cell destruction and maintained insulin production in newly diabetic NOD mice. We did a randomised, double-blind, phase II study of peptide treatment in patients with newly diagnosed (